Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
Status:
Unknown status
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing
glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin
to three separate cohorts. Study endpoints will include determination of the maximum
tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity
of MPC-6827 when given with carboplatin.